The Immunoscore® was validated as a powerful prognostic marker in colon cancer in a study conducted by the Immunoscore® worldwide consortium, led by the Society for Immunotherapy of Cancer (SITC) involving 23 pathology centers from 17 countries, and including more than 3800 patients (Galon J, et al. J Clin Oncol 34, 2016 (suppl; abstr 3500)).
HalioDx has developed a standardized version of the test that was used in this study (see Hermitte F. JITC 2016). This is the first standardized immune-based assay for the classification of cancer.
Main analytical performance of Immunoscore® Colon* system have been presented at the SITC, 31st Annual Meeting conference on the 11th of November by Fabienne Hermitte, VP, R&D – Reg & Medical Affairs – HalioDx during the Session “Promoting and Measuring Antitumor Immunity – Immunoscore® Colon Analytical Performance” and the main conclusion is that Immunoscore® Colon* is a robust, easy-to-use and accurate assay that can be used in clinical testing.
If you didn’t have the opportunity to attend this session, HalioDx is pleased to invite you to listen to its webinar on new performance data for the Immunoscore® Colon*
Register (right column) to access the replay of the webinar
*This test is for Research Use Only. Not for Diagnostic Procedures.